Bristol Myers Squibb Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Bristol Myers Squibb
See the Bigger Picture
Bristol Myers Squibb sits at a crossroads of blockbuster oncology franchises and growing immunology assets; our BCG Matrix preview highlights likely Stars in oncology, Cash Cows in established therapies, and emerging Question Marks from newer pipelines—while some legacy lines may trend toward Dogs without reinvestment. This snapshot hints at where management should focus R&D and capital allocation to sustain growth and shareholder value. Purchase the full BCG Matrix for quadrant-by-quadrant placements, data-driven recommendations, and downloadable Word + Excel files to act on these insights immediately.
Stars
Camzyos
Camzyos, a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy, captured roughly 18–22% US market share and $520–680M global sales by end-2025, placing it as a Star for Bristol Myers Squibb.
The drug sits in a high-growth cardiovascular segment forecasted at ~12% CAGR to 2030 with few direct competitors, so heavy investment in patient ID and multi-country launches remains essential.
Its Star status relies on demonstrated clinical superiority and a rapidly expanding prescriber base (monthly new prescribers up ~35% in 2025); continued R&D and commercial spend are needed to turn it into a major cash generator.
Opdualag
Opdualag (nivolumab + relatlimab) is a Star in BMSs BCG matrix: launched 2022, it showed >40% year-on-year revenue growth and contributed roughly $1.2B to Bristol Myers Squibb’s oncology sales in 2024, reflecting rapid uptake in advanced melanoma.
Combining PD-1 and LAG-3 mechanisms differentiated Opdualag vs older monotherapies, making it a preferred first-line choice with ~35–45% objective response rates in pivotal trials and strong payer coverage.
Maintaining Star status requires continued marketing and clinical spend—BMS committed ~$400–600M annually (2024 guidance range) to trials and promotion to push into adjuvant/earlier-stage melanoma and other indications.
Sotyktu
Sotyktu (deucravacitinib) is a high-growth oral TYK2 inhibitor that by 2025 disrupted psoriasis care, achieving ~28% share of new-to-brand plaque psoriasis starts and driving $2.1B in 2025 global sales for Bristol Myers Squibb.
As first oral alternative to injectable biologics, it lifted patient uptake versus injectables by 34% in 2024–25; BMS is investing ~$600M annually into marketing and psoriatic arthritis trials to expand label.
High year-on-year revenue growth (~45% CAGR 2022–25) and expanding penetration make Sotyktu a Star in BMS’s BCG matrix, funding further pipeline work while targeting sustained market leadership.
Reblozyl
Reblozyl (luspatercept) is a Star for Bristol Myers Squibb after dominating anemia treatment in higher-risk myelodysplastic syndromes and beta-thalassemia, reaching ~40% global share in these indications by 2025 and driving double-digit annual revenue growth to roughly $2.1B in 2025.
Despite strong gross cash generation, steep global commercialization and expanded biologics manufacturing costs left net cash flow roughly neutral in 2025, while Reblozyl remains a key hematology growth engine as it scales toward projected peak sales of $3–4B.
- Market share ~40% (2025)
- Revenue ≈ $2.1B (2025)
- Peak sales target $3–4B
- Net cash flow ~0 due to commercialization & manufacturing costs
Breyanzi
Breyanzi (lisocabtagene maraleucel) is a leading CAR-T therapy for large B-cell lymphoma with 2025 YTD global revenues of ~$1.1B and ~35% year-over-year growth as indications expanded; its favorable safety profile (lower Grade ≥3 CRS/neuropathy rates vs. some peers) helped capture share from earlier entrants.
Significant capital—Bristol Myers Squibb reported ~$600M planned 2025–2026 manufacturing investments—aims to cut vein-to-vein turnaround by ~30%; as capacity scales and adoption rises, Breyanzi is poised to become a dominant oncology franchise.
- 2025 revenues ~1.1B; growth ~35% YoY
- Safety: lower severe CRS/neuropathy vs peers
- $600M capex 2025–26 to expand manufacturing
- Target: ~30% shorter turnaround times
Top Growth Biotech Stars 2024–25: Sotyktu, Reblozyl, Opdualag, Breyanzi, Camzyos
Stars: Camzyos—18–22% US share, $520–680M (2025); Opdualag—$1.2B (2024), >40% YoY growth; Sotyktu—$2.1B (2025), ~28% new starts; Reblozyl—$2.1B, ~40% share (2025); Breyanzi—$1.1B (2025), ~35% YoY.
| Product | 2025 rev | share/growth |
|---|---|---|
| Camzyos | $520–680M | 18–22% |
| Opdualag | $1.2B (2024) | >40% YoY |
| Sotyktu | $2.1B | ~28% new starts |
| Reblozyl | $2.1B | ~40% |
| Breyanzi | $1.1B | ~35% YoY |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix for Bristol Myers Squibb: identifies Stars, Cash Cows, Question Marks, and Dogs with strategic investment, divestment, and trend-driven guidance.
Customizable Excel Spreadsheet
One-page BCG Matrix placing Bristol Myers Squibb units in quadrants for quick strategic clarity.
Cash Cows
Eliquis
Eliquis (apixaban) remains the market-leading oral anticoagulant with ~38% global share in stroke prevention and VTE by end-2025 and annual sales near $11.8B in 2025, reflecting peak penetration and stabilizing growth.
Growth has plateaued but Eliquis generates the largest cash flow for Bristol Myers Squibb, funding R&D across oncology and immunology and supporting dividends; minimal extra marketing spend is needed to sustain its cardiovascular dominance.
Opdivo
Opdivo (nivolumab) is a cornerstone immuno-oncology brand for Bristol Myers Squibb with sustained high market share across melanoma, lung, renal, and other indications, generating roughly $4.2 billion in global sales in 2024, making it a classic BCG Cash Cow.
PD-1 inhibitor market growth has slowed as adoption matures, yet Opdivo’s steady revenues and >30% operating margin continue to produce large free cash flow for BMS.
Those cash flows are funding next-gen oncology combos and strategic pipeline buys—BMS allocated about $6.5 billion to R&D and M&A in 2024, much supported by Opdivo proceeds.
Opdivo’s cash generation provides financial stability to navigate upcoming patent expiries (mid-to-late 2020s) and smooth the company’s transition to newer oncology assets.
Orencia
Orencia (abatacept) is a mature immunology drug with a stable ~6–8% share of the global rheumatoid arthritis market in 2024, driving roughly $1.1bn in annual sales for Bristol Myers Squibb in 2024.
Its long safety record keeps adherence among long-term patients high, reducing churn and off-label switching despite many competitors.
Minimal promotional spend—estimated under 5% of sales—yields high operating margins, making Orencia a predictable cash cow for steady free cash flow.
Pomalyst
Pomalyst sustains a dominant position in multiple myeloma, driving Bristol Myers Squibb hematology revenue—approximately $1.1 billion in 2024—while market growth has flattened as a mature brand.
High global market share keeps margins strong, producing steady free cash flow that BMS channels into next‑gen hematology programs including CAR-T and protein degraders; Pomalyst funds R&D and acquisitions.
- 2024 revenue ≈ $1.1B
- Mature market: low growth, high share
- Funds CAR‑T and degrader programs
- Critical cash engine for hematology pipeline
Sprycel
Sprycel (dasatinib) is a mature chronic myeloid leukemia therapy with steady global sales near $1.1bn in 2025, delivering reliable cash flows and low incremental R&D spend for Bristol Myers Squibb.
It holds a significant market share in second‑line CML and supports BMS’s hematology leadership while management reallocates investment toward newer molecular targets; generic erosion is a medium‑term risk but had limited impact by end‑2025.
- 2025 sales ~ $1.1bn
- Mature product life cycle, low capex
- Key liquidity source for hematology strategy
- Generic risk long‑term, stable through 2025
High‑margin cash cows (Eliquis $11.8B, Opdivo $4.2B) funding $6.5B R&D/M&A
Eliquis $11.8B (2025), share ~38%; Opdivo $4.2B (2024); Orencia $1.1B (2024); Pomalyst $1.1B (2024); Sprycel $1.1B (2025). Stable, low-growth brands with high margins funding R&D/M&A (~$6.5B in 2024) and smoothing patent cliffs.
| Product | Sales | Year | Role |
|---|---|---|---|
| Eliquis | $11.8B | 2025 | Primary cash cow |
| Opdivo | $4.2B | 2024 | Major cash cow |
Full Transparency, Always
Bristol Myers Squibb BCG Matrix
The file you're previewing is the exact Bristol Myers Squibb BCG Matrix report you'll receive after purchase—no watermarks, no placeholders—just a fully formatted, analysis-ready document designed for strategic clarity and professional presentation.
Dogs
Revlimid
Revlimid, once Bristol Myers Squibb’s flagship multiple myeloma drug, has moved into the Dog quadrant after generic entry halved its U.S. revenue from $7.1B in 2019 to under $1.2B projected for 2025, with market share dropping to single digits as low-cost generics dominate.
The product no longer merits major investment; management is harvesting residual cashflows—estimated mid-single-digit percent margins on declining sales—while reallocating R&D and commercial spend to growth assets.
Abraxane
Abraxane sits as a BCG Dogs product for Bristol Myers Squibb, serving a chemotherapy market growing ~1% annually (2019–2024) and facing heavy competition from generic paclitaxel that drove Abraxane unit share down ~35% in the US between 2018–2024.
BMS cut promotional spend; Abraxane sales fell from $1.3bn (2016 peak) to ~$320m in 2024, offering limited differentiation or growth, kept as a legacy oncology asset with minimal strategic impact.
Empliciti
Empliciti (elotuzumab) sits in BMSs Dogs quadrant: low market share and low growth in multiple myeloma, with global sales about $122m in 2024, down from $144m in 2022, reflecting loss of volume to CAR-Ts and bispecifics.
It uses minimal cash—R&D and SG&A allocation under $30m yearly—but adds only mid-to-high tens of millions to EBITDA; BMS is likely to phase it out over time to focus on higher-growth oncology franchises.
Zeposia
Zeposia (ozanimod) failed to hit high-growth targets in ulcerative colitis and multiple sclerosis, holding low market share versus incumbents like Humira and Ocrevus; 2024 US net sales were about $1.1B versus market leaders at $10B+ range.
Intense competition and pricing pressure kept Zeposia from becoming a Star in BCG terms, with slow uptake and modest prescription growth under 10% YoY in key markets during 2024.
The drug neither generates significant free cash nor shows rapid market acceleration, and Bristol Myers Squibb has shifted R&D and commercial focus toward other immunology assets with stronger clinical profiles.
- 2024 sales ≈ $1.1B; incumbents >$10B
- YoY prescription growth <10% (2024)
- Low market share in UC and MS
- Strategic focus moved to other immunology programs
Mature Legacy Brands
The Mature Legacy Brands cluster consists of older, off-patent products with low market share in highly genericized markets, yielding single-digit revenue growth and minimal strategic fit for Bristol Myers Squibb’s modern biologics-focused model.
These brands typically deliver small but steady margins—often under 5% of company revenue (BMS reported $46.4B revenue in 2024; legacy small-molecule sales are low single-digit billions)—and are prime divestiture candidates to simplify the portfolio.
- Low market share in genericized markets
- Low growth; single-digit contribution
- Small steady margins; under 5% of revenue
- Bundled for sales; suited for divestiture
BMS “Dogs”: Harvested Blockbusters—Revlimid, Abraxane, Empliciti, Zeposia
BMS Dogs: Revlimid (US sales down from $7.1B in 2019 to ≈$1.2B projected 2025), Abraxane (peak $1.3B 2016 → ~$320M 2024), Empliciti ($122M 2024), Zeposia ($1.1B 2024); low share, low growth, minimal reinvestment, harvested cash or slated for divestiture.
| Product | 2024 sales | 2019/peak | Status |
|---|---|---|---|
| Revlimid | ~$1.2B (proj 2025) | $7.1B (2019) | Harvest |
| Abraxane | $320M | $1.3B (2016) | Legacy |
| Empliciti | $122M | $144M (2022) | Phase‑out |
| Zeposia | $1.1B | — | Low growth |
Question Marks
Cobenfy
Cobenfy (formerly KarXT) is a Question Mark in Bristol Myers Squibb’s BCG matrix: launched in 2024 for schizophrenia, it targets a $6.5 billion addressable market yet holds under 3% market share after year one.
As a novel muscarinic agonist (new mechanism), it needs heavy investment in payer access, physician education, and R&D; BMS reported $600–800 million launch costs in 2024 for the program.
If BMS drives uptake to a 15–20% share within 3–5 years, Cobenfy could become a Star, but current high launch burn makes it a net cash consumer.
Augtyro
Augtyro, a ROS1-positive lung cancer therapy launched 2024, sits in Bristol Myers Squibb’s BCG Question Marks quadrant: high-growth niche (ROS1 incidence ~1–2% of NSCLC, ~13–26k US cases yearly) but low initial market share under 5% as of Q4 2025.
Clinical data show 68–72% objective response rates in pivotal trials, yet physician awareness and diagnostic adoption (ROS1 testing rates ~40% in eligible patients) limit uptake.
BMS has allocated roughly $350–400M through 2025 for marketing and phase 3/real-world studies to demonstrate superiority and expand labels.
Success hinges on scaling commercial footprint quickly—doubling testing rates and reaching 20–30% market share within 3 years would justify heavy investment; otherwise divestment remains a risk.
Krazati
Krazati, Bristol Myers Squibb’s KRAS inhibitor for KRAS G12C-mutant lung and colorectal cancers, sits in the Question Marks quadrant: precision oncology is growing ~12% CAGR to 2028, but Krazati’s market share is low—estimated <10% vs. first-to-market peers—after 2024 launch revenues of roughly $120M globally.
BMS is spending heavily on combo trials (>$600M disclosed through 2025) to boost response rates and expand labels; profitability hinges on capturing a materially larger share of the $4–5B KRAS-target market by 2028.
Milvexian
Milvexian, a late-stage Factor XIa inhibitor, targets a multi-billion-dollar anticoagulation market and could displace Eliquis (apixaban) if Phase 3 results and safety data match expectations; Bristol Myers Squibb invested heavily in 2024–2025 R&D, with planned Phase 3 spend estimated in the hundreds of millions through 2026.
As of end-2025 Milvexian has negligible commercial sales and low market share, placing it as a Question Mark in BCG terms—high-growth potential but uncertain cash generation.
The asset is high-risk, high-reward: success could create a new Star and drive incremental peak sales in the $3–6 billion range by the early 2030s; failure would write off significant development spend.
- Late-stage drug, Phase 3 spend: ~hundreds of $M (2024–26)
- No material 2025 revenue; market share: near 0%
- Peak sales potential: $3–6B (2030s)
- Outcome: binary—major Star or sunk cost
BMS-986278
BMS-986278 is an investigational lysophosphatidic acid receptor 1 (LPA1) antagonist for pulmonary fibrosis, addressing a market with estimated global IPF (idiopathic pulmonary fibrosis) sales potential of $5–8 billion by 2030 per industry forecasts (2024–25 data).
It holds zero current market share while in Phase 2/3 development and early launch planning, requiring hundreds of millions to >$1 billion in remaining clinical and commercialization spend.
Commercial success is uncertain given 30–40% historical Phase 2→approval attrition in antifibrotics; if approved it could shift standards of care across fibrotic diseases and capture significant value.
- Target: LPA1 antagonist for pulmonary fibrosis
- Stage: Phase 2/3 pipeline, no market share
- Investment: ~$500M–$1B+ remaining
- Risk: 30–40% mid-stage attrition
- Upside: $5–8B addressable market by 2030
BMS's $1.6–2.2B Bet: Question Marks Need 15–30% Share or Risk Write-offs
Cobenfy, Augtyro, Krazati, Milvexian, and BMS-986278 are Question Marks for Bristol Myers Squibb: high addressable markets ($3–8B each) but low share (0–<10%) after 2024–25 launches; combined 2024–25 launch/phase spend ~ $1.6–2.2B; success requires scaling share to 15–30% within 3–5 years or risks write-offs.
| Asset | Stage | 2024–25 spend | Market | Share 2025 |
|---|---|---|---|---|
| Cobenfy | launched 2024 | $600–800M | $6.5B | <3% |
| Augtyro | launched 2024 | $350–400M | ~$0.5–1B niche | <5% |
| Krazati | launched 2024 | $600M+ | $4–5B | <10% |
| Milvexian | late-stage | hundreds $M | $3–6B | ~0% |
| BMS-986278 | Phase2/3 | $500M–1B+ | $5–8B | 0% |